Rising Regulations And Fierce Competition Will Impede Clinical Sequencing

Not Invested

Community Contributor

Published

16 Apr 25

Updated

07 May 25

AnalystLowTarget's Fair Value

US$75.00

22.3% overvalued

10 Sep

US$91.69

-29.5%

-10.8%

-29.5%

-10.8%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$75

22.3% overvalued

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Decreased 14%

AnalystLowTarget made no meaningful changes to valuation assumptions.

AnalystLowTarget made no meaningful changes to valuation assumptions.